Redeye notes that InfraCom’s Q3 2025 report aligned with net sales estimates, but EBITDA was weighed...
Redeye provides an update following Scibase’s Q3 report and intensive news flow last Friday.
Redeye comments on EG7’s Q3-results which were close to our expectations, albeit with somewhat softe...
* Q3 Paper EBIT of ~PLN 16m vs. our PLN 5m * Challenging markets * Fair value range of SEK 17-60 Q3 ...
Investors House's Q3 report was the first since the divestment of the Apitare JV, of which Investors...
Redeye provides a brief comment on Verrica's new results from the study in BCC.
Redeye initiates coverage of Freja eID Group, a technology platform offering various e-ID solutions ...
Redeye sees the phase I results from the controlled study of semaglutide monthly depot as a success,...
Investors House reported Q3 revenues of EUR 1.4m, in line with our estimate.
RaySearch’s Q3 increases our confidence in its potential for profitable sales growth, with accelerat...
Redeye updates its estimates and valuation following Catella’s Q3 2025 report.
Enea updated its financial targets on 4 November 2025 to achieve an average CAGR of >10% over the...
* Orders grow 25%, sales 14%, adj. EBITA margin up 0.
* Q3: EBITDA of SEK 13m and a margin of 25% * We cut EBITDA by 5-2% for '26e-'27e * Currently tradin...
Redeye views Genovis’ Q3 as softer than anticipated.
